HCP Live

Dr. Lin on Combination Atezolizumab and Chemoradiation in Locally Advanced NSCLC

Jun 10, 2019

Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.

Cancer Network spoke with Steven H. Lin, MD, PhD, associate professor and radiation oncologist at The University of Texas MD Anderson Cancer Center, on the findings of a phase II trial (abstract 8512) combining atezolizumab with chemoradiation therapy in locally advanced non-small-cell lung cancer. The results were presented at ASCO 2019 in Chicago.

Related Videos

Paul Harmatz, MD, on Reducing GAGs in MPS Type 2 With RGX-121 Gene Therapy

Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade Glioma

Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy

Related Content

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

Related Content

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.